Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ
PHASE1CompletedINTERVENTIONAL
Enrollment
84
Participants
Timeline
Start Date
July 27, 2004
Study Completion Date
September 10, 2008
Conditions
Panic DisorderHealthy
Interventions
DRUG
[18F] SPA-RQ
Trial Locations (1)
20892
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda
All Listed Sponsors
lead
National Institute of Mental Health (NIMH)
NIH
NCT00088738 - Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ | Biotech Hunter | Biotech Hunter